CA
NZ
UK
AU
IND
US
AngioDynamics delivered its eighth consecutive quarter of double-digit Med Tech growth and positive adjusted EBITDA. Yet Med Tech growth slowed from 16.7 percent in the fourth quarter to 13.2 percent, guidance was reiterated rather than lifted, and the stock had gained more than 20 …
Ginkgo has pivoted from cell programming services to automated labs and data products, including Datapoints for AI models, an ARPA-H program and partnerships with Apheris and large drug makers. Revenue is shrinking, with a USD 47 million lab deal announced alongside the second-quarter loss, …
The August results lifted the shares to a 52-week high of about USD 2.79, per published reports, and the stock has since more than doubled, so a single-day drop of 5.92 percent on very light volume is modest against the move. The analyst action …
The shares moved on light volume of about 30,000 shares, so the percentage drop may reflect a thin market rather than news. The August reset assumed no improvement in academic or pharmaceutical markets, and management reorganized its commercial team and hired a new chief …
The stock climbed on ARK buying and the AI-biology rally, then fell with peers including Twist Bioscience and 10x Genomics on October 6 to 8. The screener tags the move as news, but no new October 8 company release was found. The prior August …
Several accounts describe a one-day drop of about 18.55 percent earlier this week, pushingMarket Valuefrom about USD 11 billion to USD 9.6 billion, per published reports, with analysts split on valuation. ARK sold shares on October 5, and the CEO sold about USD 923,000 …
The stock rose on spatial biology demand, AI narratives and a legal win, then fell roughly 13 to 17 percent in a session earlier this week, per market data, before slipping again. Targets from Barclays and Deutsche Bank were raised sharply, but the average …
The healthcare sector delivered a dense stretch of corporate activity this week, spanning a billion-dollar acquisition, a discontinued late-stage trial, a cleared regulatory pathway for a rare genetic disorder, and a cluster of financing moves that tell a familiar story about whereCapitalis flowing in …
AngioDynamics (NASDAQ:ANGO) announced it would report first quarter fiscal 2027 results before the open on October 8, 2026, followed by a call at 8:00 a.m. ET. This article was written before the release, so no results are known. Published market data listed a consensus …
Biohaven (NYSE:BHVN) and Ono Pharmaceutical signed an agreement on October 8, 2026 giving Ono sole rights to develop and sell Biohaven's extracellular IgG degraders in Japan, South Korea, Taiwan and ASEAN countries. The portfolio includes lead candidate BHV-1300 and follow-on candidates BHV-1310 and BHV-1320. …
Please wait processing your request...